v3.26.1
Earnings or Loss Per Share (Tables)
 6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share
The details of the calculations of our basic and diluted EPS are set forth below:
Three months ended June 30,Six months ended June 30,
2026202520262025
in millions, except per share amounts
Numerator:
Net loss attributable to Liberty Latin America shareholders$(24.0)$(423.3)$(46.7)$(559.7)
Less: Cumulative dividends on Series A Preference Shares (whether or not declared)
(1.8)— (1.8)— 
Net loss attributable to Liberty Latin America common shareholders – basic and diluted$(25.8)$(423.3)$(48.5)$(559.7)
Denominator:
Weighted average shares – basic and diluted (a)201.1 199.9 200.7 198.7 
Basic and diluted net loss per share attributable to Liberty Latin America common shareholders$(0.13)$(2.12)$(0.24)$(2.82)
(a)During the three and six months ended June 30, 2026 and 2025, we reported net losses attributable to Liberty Latin America shareholders. As a result, at June 30, 2026 and 2025 the potentially dilutive effects of the following items were not included in the computation of EPS for such periods because their inclusion would have been anti-dilutive to the computation or, in the case of certain PSUs, because such awards had not yet met the applicable performance criteria:
June 30,
20262025
in millions
Aggregate number of shares issuable pursuant to:
Outstanding options, SARs and RSUs (i)
65.2 46.1 
Outstanding PSUs and PSARs (i)
11.8 8.6 
LTVP and ESPP
6.7 8.2 
(i)    In connection with the issuance of the Series A Preference Shares in June 2026, outstanding SARs and PSARs were equitably adjusted pursuant to the anti-dilution provisions of the applicable award agreements at conversion ratios of 1.43 and 1.47 for LILA and LILAK awards, respectively, resulting in an increase to the number of shares underlying the awards presented above and a reduction in exercise prices. The 2026 amounts reflect outstanding SARs of 19.2 million and 39.2 million with weighted average exercise prices of $6.89 and $6.73 related to LILA and LILAK awards, respectively, and outstanding PSARs of 3.9 million and 7.9 million with weighted average
exercise prices of $9.69 and $9.49 related to LILA and LILAK awards, respectively. The adjustment did not result in any incremental stock-based compensation expense.